Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Wedbush

Oric Pharmaceuticals (NASDAQ:ORIC) had its price objective reduced by Wedbush from $20.00 to $17.00 in a research note published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also weighed in on ORIC. Wells Fargo & Company lifted their target price on Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Wall Street Zen raised shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Oric Pharmaceuticals in a research report on Friday, March 13th. Piper Sandler assumed coverage on shares of Oric Pharmaceuticals in a research note on Wednesday, January 7th. They set an “overweight” rating and a $22.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.90.

Oric Pharmaceuticals Price Performance

NASDAQ:ORIC opened at $7.47 on Wednesday. Oric Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $14.93. The stock’s fifty day moving average price is $11.62 and its two-hundred day moving average price is $11.31. The company has a market cap of $749.69 million, a P/E ratio of -4.91 and a beta of 1.36.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. On average, analysts expect that Oric Pharmaceuticals will post -2.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total value of $702,520.00. Following the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at $920,679.48. This trade represents a 43.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 6.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vivo Capital LLC raised its stake in Oric Pharmaceuticals by 50.3% in the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock valued at $31,735,000 after purchasing an additional 1,046,154 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Oric Pharmaceuticals by 3,646.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares in the last quarter. Royce & Associates LP increased its holdings in shares of Oric Pharmaceuticals by 521.2% in the 3rd quarter. Royce & Associates LP now owns 1,458,483 shares of the company’s stock worth $17,502,000 after buying an additional 1,223,709 shares during the last quarter. Alkeon Capital Management LLC increased its holdings in shares of Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock worth $45,717,000 after buying an additional 500,000 shares during the last quarter. Finally, Resolute Capital Asset Partners LLC purchased a new stake in shares of Oric Pharmaceuticals during the 2nd quarter valued at $2,309,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

More Oric Pharmaceuticals News

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: Company selected rinzimetostat 400 mg once daily as the RP3D in combination with darolutamide and plans to start the Himalayas‑1 registrational Phase 3 in 1H 2026 — a clear clinical progress milestone that advances the program toward potential registration. ORIC Reports RP3D Selection (GlobeNewswire)
• Positive Sentiment: Press coverage highlights Oric moving into Phase 3 and positioning its candidate against competitors (e.g., Pfizer), which could increase program value if registrational endpoints are met. Oric chases Pfizer into phase 3 (FierceBiotech)
• Neutral Sentiment: Analyst reaction was mixed: Wedbush cut its price target from $20 to $17 but maintained an “outperform” rating, signaling continued institutional conviction despite the recent risk repricing. Wedbush price target update (Benzinga)
• Negative Sentiment: Investors dumped shares after the Phase 1b update revealed safety/tolerability issues at higher doses and side‑effect data that raised questions about the optimal therapeutic window, prompting an after‑hours drop and heavy intraday volume. ORIC drops after trial data (Seeking Alpha)
• Negative Sentiment: Mainstream reports emphasize safety/side‑effect concerns tied to the combo regimen and note the stock’s sharp fall, reinforcing negative investor sentiment in the short term. Shares fall on side-effect data (MarketWatch)

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.